Monthly Prescribing Reference (registration) |
Nucala Now Available for Severe Asthma
Monthly Prescribing Reference (registration) GlaxoSmithKline announced the launch of Nucala (mepolizumab) subcutaneous injection for the treatment of patients aged ?12 years with severe asthma with an eosinophilic phenotype. Nucala, the first biologic add-on therapy approved for this condition, … GSK Announces NucalaB. (mepolizumab), Now Available In The Us For Sub-Group Of … GSK Says Nucala Available In U.S. For Sub-group Of Patients With Severe Asthma |
View full post on asthma – Google News